• Nocodazole and the Cellular Entry of Spiroplasma

  2026-10-18

  Wei et al. used Drosophila S2 cells to examine how Spiroplasma eriocheiris enters and affects host cells. Their findings implicated clathrin-mediated endocytosis, macropinocytosis, and the actin–microtubule cytoskeleton, while also showing that nocodazole-sensitive reductions in intracellular bacterial copy number cannot by themselves distinguish impaired entry from altered trafficking, replication, survival, or host-cell physiology.

• 2-NBDG Assay: Mechanism and Evidence Boundaries

  2026-10-17

  The APExBIO product page identifies K2212 as a non-radioactive fluorescent assay based on 2-NBDG, but no identity-matched study is available to establish performance, effect sizes, or application-specific validity.

• When E-64 Results Change Meaning Across Models

  2026-10-16

  A result from E-64 research cannot be separated from its model, comparator, molecular target, and readout. In Dahl salt-sensitive rats, chronic cysteine cathepsin inhibition was associated with evidence of target engagement but did not alter hypertension, albuminuria, podocyte calcium, or reported renal injury. The study therefore narrows a disease-specific claim rather than disproving cathepsin biology generally. This editorial examines how biochemical inhibition, pharmacodynamic markers, and physiological outcomes can diverge, and why those distinctions define the limits of interpretation.

• Etazolate Hydrochloride: Evidence Boundaries

  2026-10-16

  The available APExBIO listing identifies Etazolate hydrochloride as catalog product B6304, but it supplies no product description or identity-matched research evidence. Accordingly, a defensible scientific overview can address catalog identity and evidence boundaries, but not a molecular mechanism, assay interpretation, biological activity, or comparative performance.

• Fluorescein-12-dUTP: What Is Documented

  2026-10-15

  APExBIO identifies Fluorescein-12-dUTP as product B8207, but the available product record provides no description and no identity-matched research study is available. The chemical name supports a cautious, class-level interpretation: a fluorescently labeled deoxyuridine triphosphate intended, in principle, to connect nucleotide incorporation with an optical readout. That interpretation does not establish product-specific incorporation, assay performance, specificity, or suitability for any application.

• How MLN2238 Reveals the CRTC–CREB Stress Axis

  2026-10-15

  The cited study used MLN2238 as a proteasome-inhibition perturbation to identify a ROS–JNK–CRTC/CREB response to proteotoxic stress in Drosophila. Its evidence supports a mechanistic model in which proteasome dysfunction activates protective transcriptional programs, while the fly and cell-based systems limit direct conclusions about human disease, oncology, or clinical treatment.

• Protease Inhibitor Cocktail: Evidence and Scope

  2026-10-14

  The APExBIO product page identifies K4007 as an EDTA-free, 100X aqueous protease inhibitor cocktail, but it does not disclose composition, target spectrum, assay data, or identity-matched research. Its mechanism can therefore be discussed only at the level of general protease inhibition, while claims about performance, compatibility, or application-specific efficacy remain unsupported.

• 7-Dehydrocholesterol: What the Evidence Shows

  2026-10-14

  7-Dehydrocholesterol is a sterol intermediate linking cholesterol metabolism with vitamin D biology. A 2026 grass carp study associated dhcr7 disruption with greater resistance to GCRV-II, but the findings concern genetic alteration in one fish species—not 7-dehydrocholesterol supplementation, antiviral treatment, or evidence applicable to humans.

• E-64 in Salt-Sensitive Hypertension: What the Study Shows

  2026-10-13

  A 2016 rat study found that chronic E-64 exposure did not alter hypertension, albuminuria, or basal podocyte calcium in a Dahl salt-sensitive model. The result is informative but limited to this animal model and to broad cysteine protease inhibition under the reported conditions.

• Phosbind Biotin LC: Evidence and Scope

  2026-10-13

  Phosbind Biotin LC is a supplier-described phosphate-binding reagent for sequence-independent phosphorylated protein detection on PVDF membranes. The available evidence establishes product identity and intended conceptual use, but does not independently verify sensitivity, specificity, performance, or broader applicability.

• E-64d and the Limits of Cell-Death Inference

  2026-10-12

  The supplied study evaluates MEDUSA, a modeling framework for separating drug-associated changes in cellular growth and death rates. Its findings clarify how p53 status can influence DNA-damage-induced death in the studied cell models, but they do not establish a role for E-64d, calpain, or cathepsins in that mechanism. Supplier-described uses of E-64d therefore require cautious interpretation and cannot substitute for target-specific genetic or biochemical evidence.

• Sulfo-NHS-LC-Biotin: Identity and Scope

  2026-10-12

  Sulfo-NHS-LC-Biotin, also identified as sulfosuccinimidyl-6-(biotinamido) hexanoate, is documented by APExBIO as a water-compatible reagent for covalent biotin labeling of accessible primary amines. The available evidence is limited to supplier information: no matched research paper was provided, so performance claims, comparative advantages, quantitative outcomes, and broader biological applicability cannot be independently assessed here.

• Lysoptosis and the Limits of Protease Inference

  2026-10-11

  Luke et al. present lysoptosis as a distinct, evolutionarily conserved lysosome-dependent cell-death pathway revealed by loss of intracellular serpin protection. The evidence supports a role for lysosomal membrane permeabilization and cathepsin-dependent proteolysis, while leaving broader tissue, disease and therapeutic applicability unresolved.

• Reserpine N1867: Product Identity and Evidence Limits

  2026-10-10

  Reserpine (SKU N1867) is a supplier-described natural product from Rauvolfia plants with reported purity above 98.8%. The available information supports product identity and conceptual research scope, but no matched paper evidence was provided to validate performance, mechanisms, or outcomes.

• Cathepsin B and L Proteases in Barley Senescence

  2026-10-09

  Schepetkin and Fischer connect developmental barley leaf senescence with increased cathepsin B- and L-like cysteine protease activity by combining substrate-based assays, inhibitor profiling, activity-probe labeling, and immunoblotting. The study supports a role for papain-like proteases in senescence-associated protein turnover, while also showing why inhibitor responses alone cannot establish the contribution of a single cathepsin subtype.

8012 records 1/535 page Next 12345 下5页 Last page